Perthera develops a Precision Cancer Analysis (PCA) that uses comprehensive multi-omic molecular testing to produce detailed, personalized treatment plans and identify clinical trial options. Its workflow emphasizes tissue protection, best-in-class molecular assays, and a growing databank of prior treatment histories and patient outcomes to improve treatment matching. A proprietary software platform automates PCA creation, integrates historical data, and produces individualized analyses that aim to improve patient experience and medical success. Perthera also convenes a Virtual Tumor Board of leading oncologists to provide virtual second opinions alongside the PCA. The company reports adoption by hundreds of oncology practices, including respected cancer centers and hospitals across the United States. Perthera is based in the Tysons Corner area of Northern Virginia and is positioning the PCA as a first step in cancer treatment pathways worldwide.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2016